Patent 11104660 was granted and assigned to Tetra Therapeutics on August, 2021 by the United States Patent and Trademark Office.
Provided herein are phosphodiesterase 4D (PDE4D) inhibitors, including methods of using the same. Also provided are methods of treating subjects suffering from conditions associated with aberrant PDE activity.